Your browser doesn't support javascript.
loading
Clinical Profile Among Brazilian Mucopolysaccharidosis type II Patients: Subgroup Analysis from the Hunter Outcome Survey
Horovitz, Dafne D G; Ribeiro, Márcia G; Acosta, Angelina X; Monteiro, Ana C; Botha, Jaco; Giugliani, Roberto.
  • Horovitz, Dafne D G; Fundação Oswaldo Cruz. Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira. Rio de Janeiro. BR
  • Ribeiro, Márcia G; Universidade Federal do Rio de Janeiro. Instituto de Puericultura e Pediatria Martagão Gesteira. Rio de Janeiro. BR
  • Acosta, Angelina X; Universidade Federal da Bahia. Faculdade de Medicina da Bahia Departamento de Pediatria. Salvador. BR
  • Monteiro, Ana C; Takeda. Departamento de Assuntos Médicos. São Paulo. BR
  • Botha, Jaco; Takeda Pharmaceuticals International AG. Opfikon. Zürich. CH
  • Giugliani, Roberto; Universidade Federal do Rio Grande do Sul. Serviço de Genética Médica. Programa de Pós-Graduação em Genética e Biologia Molecular. Porto Alegre. BR
J. inborn errors metab. screen ; 11: e2023002, 2023. tab, graf
Article Dans Anglais | LILACS-Express | LILACS | ID: biblio-1506621
ABSTRACT
Abstract Mucopolysaccharidosis type II (MPS II) is a rare genetic, multiorgan disease. Little information about the Brazilian context is available to date; thus, this descriptive subgroup analysis was conducted on Brazilian data from the Hunter Outcome Survey (HOS), including clinical characteristics among MPS II patients from Brazil. HOS is a global, multi-center, long-term, observational registry of patients with MPS II (NCT03292887). Variables related to organ system involvement, signs and symptoms, surgical procedures and survival among Brazilian patients were extracted from HOS database. Data from 153 Brazilian patients with MPS II were analyzed. Musculoskeletal (96.6%), abdomen/gastrointestinal (95.2%), neurological (88.7%), pulmonary (86.2%), and ear (81.3%) were the most frequently observed organ/systems involved. Regarding signs and symptoms, the most prevalent symptom was coarse facial features consistent with the disease (94.6%), followed by joint stiffness and limited function (89.3%), hernia (84.2%) and hepatomegaly (82.2%). Median survival time was 22.0 years, and the major cause of death was respiratory failure (31.8%). These data may be helpful to understand disease characteristics and to help improve the quality of MPS II patient care in Brazil.


Texte intégral: Disponible Indice: LILAS (Amériques) Pays comme sujet: Amérique du Sud / Brésil langue: Anglais Texte intégral: J. inborn errors metab. screen Thème du journal: Medicina Cl¡nica / Patologia Année: 2023 Type: Article Pays d'affiliation: Brésil / Suisse Institution/Pays d'affiliation: Fundação Oswaldo Cruz/BR / Takeda Pharmaceuticals International AG/CH / Takeda/BR / Universidade Federal da Bahia/BR / Universidade Federal do Rio Grande do Sul/BR / Universidade Federal do Rio de Janeiro/BR

Documents relatifs à ce sujet

MEDLINE

...
LILACS

LIS


Texte intégral: Disponible Indice: LILAS (Amériques) Pays comme sujet: Amérique du Sud / Brésil langue: Anglais Texte intégral: J. inborn errors metab. screen Thème du journal: Medicina Cl¡nica / Patologia Année: 2023 Type: Article Pays d'affiliation: Brésil / Suisse Institution/Pays d'affiliation: Fundação Oswaldo Cruz/BR / Takeda Pharmaceuticals International AG/CH / Takeda/BR / Universidade Federal da Bahia/BR / Universidade Federal do Rio Grande do Sul/BR / Universidade Federal do Rio de Janeiro/BR